Literature DB >> 9049413

Rapid degradation of CD4 in cells expressing human immunodeficiency virus type 1 Env and Vpu is blocked by proteasome inhibitors.

K Fujita1, S Omura, J Silver.   

Abstract

Human immunodeficiency virus (HIV) type 1 encodes three genes, Vpu, Env and Nef, that decrease cellular CD4. Vpu and Env act cooperatively to accelerate degradation of CD4 in the endoplasmic reticulum. Here we report that Vpu/Env-induced CD4 degradation is inhibited by lactacystin, a specific inhibitor of the proteasome, and by other proteasome inhibitors, but not by non-proteasome protease inhibitors. We also note that Vpu has amino acid sequence homology with a segment of IkappaB known to be involved in proteasome-mediated degradation, suggesting that HIV-1 could have transduced cellular sequences to enhance down-regulation of CD4.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049413     DOI: 10.1099/0022-1317-78-3-619

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  36 in total

1.  Degradation of tobacco mosaic virus movement protein by the 26S proteasome.

Authors:  C Reichel; R N Beachy
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus.

Authors:  S Gummuluru; C M Kinsey; M Emerman
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens.

Authors:  Patrick M Glassman; Joseph P Balthasar
Journal:  MAbs       Date:  2016-11-28       Impact factor: 5.857

4.  HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.

Authors:  Yukie Iwabu; Hideaki Fujita; Masanobu Kinomoto; Keiko Kaneko; Yukihito Ishizaka; Yoshitaka Tanaka; Tetsutaro Sata; Kenzo Tokunaga
Journal:  J Biol Chem       Date:  2009-10-16       Impact factor: 5.157

5.  Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation.

Authors:  Amjad Hussain; Clement Wesley; Mohammad Khalid; Ashutosh Chaudhry; Shahid Jameel
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

6.  Modulation of the severe CD4+ T-cell loss caused by a pathogenic simian-human immunodeficiency virus by replacement of the subtype B vpu with the vpu from a subtype C HIV-1 clinical isolate.

Authors:  M Sarah Hill; Autumn Ruiz; Erik Pacyniak; David M Pinson; Nathan Culley; Bonnie Yen; Scott W Wong; Edward B Stephens
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

Review 7.  Tools for Visualizing HIV in Cure Research.

Authors:  Julia Niessl; Amy E Baxter; Daniel E Kaufmann
Journal:  Curr HIV/AIDS Rep       Date:  2018-02       Impact factor: 5.071

8.  Identification of amino acids within the second alpha helical domain of the human immunodeficiency virus type 1 Vpu that are critical for preventing CD4 cell surface expression.

Authors:  M Sarah Hill; Autumn Ruiz; Kimberly Schmitt; Edward B Stephens
Journal:  Virology       Date:  2009-11-27       Impact factor: 3.616

Review 9.  Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection.

Authors:  Samuele E Burastero; Mariangela Figini; Barbara Frigerio; Paolo Lusso; Luca Mollica; Lucia Lopalco
Journal:  J Transl Med       Date:  2009-11-28       Impact factor: 5.531

10.  Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors.

Authors:  Ilias Christodoulopoulos; Magali E Droniou-Bonzom; Jill E Oldenburg; Paula M Cannon
Journal:  Retrovirology       Date:  2010-01-26       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.